Figure 7
Ganetespib significantly inhibits ErbB2-overexpressing mammary tumors in vivo in a syngeneic transplantation mouse model. 10-week-old MMTV-ErbB2 mice (N = 6 mice per group) were subcutaneously injected with 78617 cells for syngeneic tumor growth. Once tumors were palpable 8 days after the initial tumor cell inoculations, ganetespib (30 mg/kg) was administered via i.p. injections every other day until the 20th day after tumor cell inoculations. Tumor volumes were measured every 2 days. All values are presented as the means ± S.E. (**P ≤ 0.01).
